S&P 500   4,587.71 (+0.44%)
DOW   36,182.83 (+0.65%)
QQQ   389.53 (+0.18%)
AAPL   191.00 (+0.55%)
MSFT   373.40 (-1.45%)
META   322.47 (-1.43%)
GOOGL   131.64 (-0.67%)
AMZN   146.62 (+0.36%)
TSLA   238.65 (-0.60%)
NVDA   469.24 (+0.33%)
NIO   7.19 (-1.10%)
BABA   73.53 (-1.80%)
AMD   121.03 (-0.11%)
T   16.61 (+0.24%)
F   10.51 (+2.44%)
MU   75.88 (-0.32%)
CGC   0.62 (+9.98%)
GE   122.78 (+0.80%)
DIS   92.43 (-0.28%)
AMC   6.85 (+3.01%)
PFE   29.14 (-4.36%)
PYPL   59.35 (+3.02%)
XOM   102.92 (+0.18%)
S&P 500   4,587.71 (+0.44%)
DOW   36,182.83 (+0.65%)
QQQ   389.53 (+0.18%)
AAPL   191.00 (+0.55%)
MSFT   373.40 (-1.45%)
META   322.47 (-1.43%)
GOOGL   131.64 (-0.67%)
AMZN   146.62 (+0.36%)
TSLA   238.65 (-0.60%)
NVDA   469.24 (+0.33%)
NIO   7.19 (-1.10%)
BABA   73.53 (-1.80%)
AMD   121.03 (-0.11%)
T   16.61 (+0.24%)
F   10.51 (+2.44%)
MU   75.88 (-0.32%)
CGC   0.62 (+9.98%)
GE   122.78 (+0.80%)
DIS   92.43 (-0.28%)
AMC   6.85 (+3.01%)
PFE   29.14 (-4.36%)
PYPL   59.35 (+3.02%)
XOM   102.92 (+0.18%)
S&P 500   4,587.71 (+0.44%)
DOW   36,182.83 (+0.65%)
QQQ   389.53 (+0.18%)
AAPL   191.00 (+0.55%)
MSFT   373.40 (-1.45%)
META   322.47 (-1.43%)
GOOGL   131.64 (-0.67%)
AMZN   146.62 (+0.36%)
TSLA   238.65 (-0.60%)
NVDA   469.24 (+0.33%)
NIO   7.19 (-1.10%)
BABA   73.53 (-1.80%)
AMD   121.03 (-0.11%)
T   16.61 (+0.24%)
F   10.51 (+2.44%)
MU   75.88 (-0.32%)
CGC   0.62 (+9.98%)
GE   122.78 (+0.80%)
DIS   92.43 (-0.28%)
AMC   6.85 (+3.01%)
PFE   29.14 (-4.36%)
PYPL   59.35 (+3.02%)
XOM   102.92 (+0.18%)
S&P 500   4,587.71 (+0.44%)
DOW   36,182.83 (+0.65%)
QQQ   389.53 (+0.18%)
AAPL   191.00 (+0.55%)
MSFT   373.40 (-1.45%)
META   322.47 (-1.43%)
GOOGL   131.64 (-0.67%)
AMZN   146.62 (+0.36%)
TSLA   238.65 (-0.60%)
NVDA   469.24 (+0.33%)
NIO   7.19 (-1.10%)
BABA   73.53 (-1.80%)
AMD   121.03 (-0.11%)
T   16.61 (+0.24%)
F   10.51 (+2.44%)
MU   75.88 (-0.32%)
CGC   0.62 (+9.98%)
GE   122.78 (+0.80%)
DIS   92.43 (-0.28%)
AMC   6.85 (+3.01%)
PFE   29.14 (-4.36%)
PYPL   59.35 (+3.02%)
XOM   102.92 (+0.18%)

Infinity Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INFI)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.01
▼
$0.13
52-Week Range
N/A
Volume
2.48 million shs
Average Volume
2.58 million shs
Market Capitalization
$726,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media

INFI stock logo

About Infinity Pharmaceuticals Stock (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.


INFI Stock News Headlines

December 1, 2023 | seekingalpha.com
INFIQ Infinity Pharmaceuticals, Inc.
October 16, 2023 | businesswire.com
INFI DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities ...
December 1, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
October 16, 2023 | barrons.com
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
October 15, 2023 | stockhouse.com
Infinity Ongoing Deadline Alert
October 14, 2023 | bloomberg.com
Deadline Alert: Bronstein, Gewirtz & Grossman LLC Announces that Infinity Pharmaceuticals, Inc. (INFI) Investors Have Opportuni
October 10, 2023 | finance.yahoo.com
Infinity Pharmaceuticals, Inc. (INFIQ)
October 9, 2023 | barrons.com
Bronstein, Gewirtz & Grossman LLC Notifies Infinity Pharmaceuticals, Inc. (INFI) Investors of Class Action and to Actively Participate!
December 1, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
October 2, 2023 | bizjournals.com
Gutted Cambridge biotech declares bankruptcy after failed merger, layoffs
October 1, 2023 | markets.businessinsider.com
Infinity Investor Shareholder Alert
September 29, 2023 | msn.com
Infinity Pharmaceuticals reportedly files for Chapter 11
September 22, 2023 | finanznachrichten.de
Faron Pharmaceuticals Oy: Faron Pharmaceuticals Announces Board Changes
September 18, 2023 | stockhouse.com
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 16, 2023 | prnewswire.com
INFINITY DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options
September 16, 2023 | markets.businessinsider.com
ROSEN, A TOP RANKED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI
September 15, 2023 | stockhouse.com
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 14, 2023 | stockhouse.com
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 13, 2023 | gurufocus.com
Director Adelene Perkins Sells 410,196 Shares of Infinity Pharmaceuticals Inc (INFI)
September 13, 2023 | stockhouse.com
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 13, 2023 | seekingalpha.com
Infinity Pharmaceuticals receives delisting determination letter from Nasdaq
September 11, 2023 | stockhouse.com
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 6, 2023 | benzinga.com
INFI Stockholders Should Contact Robbins LLP for Information About the Class Action Involving Infinity Pharmaceuticals, Inc.
September 6, 2023 | stockhouse.com
Infinity Shareholder Notice
September 6, 2023 | finanznachrichten.de
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 5, 2023 | finance.yahoo.com
Three execs leave Infinity Pharmaceuticals after failed merger, layoffs
September 2, 2023 | stockhouse.com
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
See More Headlines
Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
12/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INFI
CUSIP
45665G30
CIK
1113148
Web
www.infi.com
Phone
(617) 453-1000
Fax
617-453-1001
Employees
30
Year Founded
2000

Profitability

EPS (Most Recent Fiscal Year)
($0.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-44,370,000.00
Net Margins
-1,593.93%
Pretax Margin
-1,593.93%
Return on Equity
N/A
Return on Assets
-113.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.65
Quick Ratio
1.65

Sales & Book Value

Annual Sales
$2.59 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.21) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
90,760,000
Free Float
81,857,000
Market Cap
$726,000.00
Optionable
Optionable
Beta
1.63

Social Links

5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Lawrence E. Bloch J.D. (Age 57)
    M.D., Treasurer
    Comp: $513.61k
  • Mr. Seth A. Tasker J.D. (Age 44)
    CEO, Sr. VP, Gen. Counsel & Sec.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions














INFI Stock Analysis - Frequently Asked Questions

Should I buy or sell Infinity Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares.
View INFI analyst ratings or view top-rated stocks.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to analyst estimates of $0.45 million. During the same quarter in the previous year, the company earned ($0.16) earnings per share.

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il.
View institutional ownership trends.

This page (NASDAQ:INFI) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -